Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network SignalingAccesswire • 04/12/21
How A Pfizer Cancer Drug Pact Launched Celcuity Stock Into A BreakoutInvestors Business Daily • 04/09/21
Celcuity Stock Moves Higher After Licensing Pact With Pfizer For Gedatolisib In Breast CancerBenzinga • 04/09/21
Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate UpdateBusiness Wire • 04/08/21
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast CancerBusiness Wire • 04/08/21
Celcuity Teams Up With MD Anderson, Novartis, Puma Biotech To Study New Drug Regimen In Breast CancerBenzinga • 03/17/21
Celcuity Announces Closing of Common Stock Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares of Common StockAccesswire • 03/01/21
Celcuity Announces Clinical Trial Collaboration with Massachusetts General Hospital and Puma BiotechnologyAccesswire • 12/23/20
Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/09/20
Celcuity Inc. (CELC) CEO Brian Sullivan on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/10/20
Celcuity Inc. (CELC) CEO Brian Sullivan on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/13/20
Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/10/19
All You Need to Know About Celcuity, Inc. (CELC) Rating Upgrade to BuyZacks Investment Research • 11/01/19
Celcuity's (CELC) CEO Brian Sullivan on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/10/19
Celcuity, Inc. (CELC) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 05/13/19